Pixium vision announces the 48-month trial results in severe atrophic amd

Pixium vision announces the 48-month trial results in severe atrophic amd study confirms subretinal prothesis feasible and well-tolerated with no reduction of natural peripheral vision, confirming 36-month results patients suffering from central vision loss reliably recognized letters and sequences of letters, a clinically significant improvement full data readout of accompanying pivotal primavera trial expected early 2024 pixium vision reiterates that it is subject to receivership proceedings and is actively seeking buyers for its assets paris, france, 14, 202 3 – 7:00 am (cet) – pixium vision sa (euronext growth paris - fr001400jx97; mnemo: alpix), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, today announces data from a first in human trial to assess the efficacy and safety of the prima photovoltaic retinal stimulation microchip for improving visual acuity (va) 48 months post implantation in patients with severe central vision impairment due to dry age-related macular degeneration (dry amd) the trial data show that the implantation of prima is feasible and well tolerated in all five study participants, with no reduction of natural peripheral visual function after 48 months. using the prosthetic central vision provided by prima, patients reliably recognized letters and sequences of letters with a clinically meaningful improvement in visual acuity of up to eight lines.
AMD Ratings Summary
AMD Quant Ranking